Pharmaceutical company intelligence reports from Espicom provide a full review of the company's activities together with five-year sales forecasts for its key products. The company's financial performance is covered in-depth, from its latest results to a complete analysis of its latest full fiscal year and an outlook for the future. A section on company strategy covers mergers, acquisitions and divestitures, key agreements, products and R&D. An overview of key products and R&D is followed by a comprehensive review of the company's product portfolio and research and development pipeline by therapeutic area. In addition, supplementary appendices provide more in-depth information on financials, agreements and corporate events. Shionogi operates in a number of business fields, and principal among these is its Pharmaceuticals segment. Within this business segment, Shionogi is active in the following therapeutic areas: Infectious Diseases, Metabolic Syndrome, Anticancer, Neurology, Allergy and Circulatory. As part of Shionogi's Second Medium-Term Management Plan (which began in April 2005, and runs until fiscal 2010), the company is planning to focus research efforts specifically on the treatment of infections, pain and metabolic syndrome.

Within Japan, Shionogi is recognised as one of the leading antibiotics' companies and in recent years, Flomox, Flumarin and Vancomycin have all maintained their positions as top sellers in their product categories. However, a contracting antibiotic market and increased competition have impacted negatively on sales. To address this issue Shionogi has developed and launched Finibax (September 2005), and licensed-in Bayer's Avelox (launched in Japan in December 2005).

To ensure long-term growth, Shionogi has succeeded in developing an encouraging pipeline containing several promising candidate drugs, most notably duloxetine, irbesartan and S-013420. As one of the smaller pharmaceutical companies in Japan, this has largely been achieved through in-licensing. Shionogi is concentrating resources in the three target areas of infection, pain and metabolic syndrome, with the aim of advancing at least five new chemical compounds to Phase II or more advanced stages by the end of fiscal 2009. At present, three compounds have advanced to the development stage: S-2367, S-364735 and S-777469.

Shionogi has a limited global profile, but has achieved substantial success from out-licensing major products in overseas markets to maximise their sales values and utilise the marketing infrastructures of overseas companies. Crestor, which is licensed to AstraZeneca in the US and Europe, has been particularly profitable in terms of royalty payments. The US development of Finibax is being conducted by Peninsula Pharmaceuticals (now acquired by Johnson & Johnson) and with an anticipated filing in 2006, Shionogi now has the possibility of overseas expansion in the antibiotics' field.

This new strategic analysis report Shionogi: Performance, Products, Pipeline and Potential, provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. The report is updated on a quarterly basis. Buyers of the web edition receive quarterly reports for a year. Buyers of the print/pdf editions receive the latest version. All formats are the same price.